AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37316785 — intervention group
Group type: EXPERIMENTAL
Intervention: Days alive without life support (DAWOLS)
Number of subjects: 0
Study 37316785 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex regression models (hurdle-negative binomial, zero-one-inflated beta, cumulative logistic regression)
Number of subjects: 0
Study 37316785 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex models
Number of subjects: 0
Study 37316789 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 0
Study 37316789 — intervention group
Group type: COMPARATOR
Intervention: Regional Anesthesia
Number of subjects: 0
Study 37316789 — intervention group
Group type: COMPARATOR
Intervention: Combination of General Anesthesia and Regional Anesthesia
Number of subjects: 0
Study 37316789 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction Phase of Anesthesia
Number of subjects: 0
Study 37316789 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical Incidents
Number of subjects: 0
Study 37316843 — intervention group
Group type: EXPERIMENTAL
Intervention: Process improvement (text messages)
Number of subjects: 0
Study 37316843 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier elicitation and reduction (electronic survey with tailored questions/prompts)
Number of subjects: 0
Study 37316843 — intervention group
Group type: EXPERIMENTAL
Intervention: Teachable moment messaging (motivational interviewing)
Number of subjects: 0
Study 37316847 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin therapy
Number of subjects: 2990
Study 37316885 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop automated oxygen control (CLAC)
Number of subjects: 40
Study 37316885 — intervention group
Group type: COMPARATOR
Intervention: Manual oxygen control
Number of subjects: 40
Study 37316919 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous monitoring with a wearable sensor (heart rate, respiratory rate, posture, and activity) for 14 days
Number of subjects: 800
Study 37316919 — intervention group
Group type: COMPARATOR
Intervention: Usual care without continuous monitoring
Number of subjects: 800
Study 37316919 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous monitoring
Number of subjects: 800
Study 37317022 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab 200 mg SC every 4 weeks through Week 36
Number of subjects: 100
Study 37317022 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab 1200 mg IV for 12 weeks, then switched to guselkumab 200 mg SC every 4 weeks from Weeks 12 through 36
Number of subjects: 100
Study 37317022 — intervention group
Group type: COMPARATOR
Intervention: placebo for 12 weeks, then re-randomized to guselkumab 200 mg SC every 4 weeks or guselkumab 100 mg SC at specified weeks
Number of subjects: 100
Study 37317676 — intervention group
Group type: EXPERIMENTAL
Intervention: Customizable educational brochure
Number of subjects: 165
Study 37317676 — intervention group
Group type: COMPARATOR
Intervention: Standard educational brochure
Number of subjects: 165
Study 37317838 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilaterally selective adrenal vein sampling
Number of subjects: 1625
Study 37317838 — intervention group
Group type: COMPARATOR
Intervention: RASI values ≤0.96 and >2.55 in patients without unilateral primary aldosteronism
Number of subjects: 1625
Study 37317841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Number of subjects: 43
Study 37317866 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency renal denervation (RDN)
Number of subjects: 2746
Study 37317993 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib (BKM120) monotherapy
Number of subjects: 4
Study 37318023 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional balloon angioplasty
Number of subjects: 2895
Study 37318023 — intervention group
Group type: EXPERIMENTAL
Intervention: Major adverse limb events (composite of all-cause death, target limb revascularization, or major amputation)
Number of subjects: 2895
Study 37318085 — intervention group
Group type: EXPERIMENTAL
Intervention: Avatrombopag (AVA) at a starting dose of 20 mg/d, titrated to a maximum of 60 mg/d
Number of subjects: 25
Study 37318116 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA)
Number of subjects: 4978
Study 37318116 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS/LABA + long-acting muscarinic antagonist (LAMA)
Number of subjects: 4978
Study 37318116 — intervention group
Group type: EXPERIMENTAL
Intervention: LAMA monotherapy
Number of subjects: 4978
Study 37318116 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting inhalers
Number of subjects: 4978
Study 37318116 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS-containing therapy
Number of subjects: 4978
Study 37318116 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD assessment test score
Number of subjects: 4978
Study 37318116 — intervention group
Group type: EXPERIMENTAL
Intervention: Exacerbation rates
Number of subjects: 4978
Study 37318116 — intervention group
Group type: EXPERIMENTAL
Intervention: Exacerbation requiring hospitalization/emergency visit
Number of subjects: 4978
Study 37318116 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence for long-acting inhalers
Number of subjects: 4978
Study 37318116 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD questionnaire score
Number of subjects: 4978
Study 37318140 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypercapnia (target Paco2 not specified) for 24 hours
Number of subjects: 1700
Study 37318140 — intervention group
Group type: COMPARATOR
Intervention: Normocapnia (target Paco2 not specified) for 24 hours
Number of subjects: 1700
Study 37318215 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model for classifying tympanometry tracings acquired by layperson
Number of subjects: 1635
Study 37318215 — intervention group
Group type: COMPARATOR
Intervention: Tympanometer's built-in classifier
Number of subjects: 1635
Study 37318215 — intervention group
Group type: COMPARATOR
Intervention: Decision tree based on clinically recommended normative values
Number of subjects: 1635
Study 37318215 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model for classifying tympanometry tracings acquired by audiologist
Number of subjects: 1635
Study 37318279 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative behavioral and pelvic floor muscle training
Number of subjects: 0
Study 37318279 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 37318349 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib 1 mg once daily for 24 weeks
Number of subjects: 61
Study 37318379 — intervention group
Group type: EXPERIMENTAL
Intervention: Tucatinib in combination with Trastuzumab
Number of subjects: 84
Study 37318415 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 194
Study 37318415 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 194
Study 37318415 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 194
Study 37318419 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4269
Study 37318419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4269
Study 37318428 — intervention group
Group type: EXPERIMENTAL
Intervention: OPEN
Number of subjects: 1746
Study 37318428 — intervention group
Group type: COMPARATOR
Intervention: ENDO
Number of subjects: 1746
Study 37318469 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine infiltration along the nephrostomy tract (20 mL)
Number of subjects: 50
Study 37318469 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bupivacaine infiltration)
Number of subjects: 50
Study 37318469 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine infiltration
Number of subjects: 50
Study 37318549 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-stroke fatigue (PSF) assessed using the Swedish version of the Fatigue Assessment Scale (S-FAS), defined as S-FAS score ≥ 24.
Number of subjects: 305
Study 37318549 — intervention group
Group type: EXPERIMENTAL
Intervention: High body mass index (BMI) as a predictor of PSF.
Number of subjects: 305
Study 37318580 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (IG)
Number of subjects: 68
Study 37318580 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (CG)
Number of subjects: 68
Study 37318673 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal artery diameter measurement using optical coherence tomography-angiography (OCT-A)
Number of subjects: 77
Study 37318685 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin for 6 months
Number of subjects: 100
Study 37318685 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 100
Study 37318707 — intervention group
Group type: EXPERIMENTAL
Intervention: LipiFlow treatment prior to cataract surgery
Number of subjects: 121
Study 37318707 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LipiFlow treatment prior to surgery)
Number of subjects: 121
Study 37318707 — intervention group
Group type: COMPARATOR
Intervention: Control group after crossover (received LipiFlow treatment)
Number of subjects: 121
Study 37318750 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg Q2W
Number of subjects: 206
Study 37318803 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month PrEP dispensing with semiannual clinic visits and interim HIV self-testing at 3 months
Number of subjects: 495
Study 37318803 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) PrEP delivery with 3-month dispensing and quarterly clinic visits
Number of subjects: 495
Study 37318808 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram, Sertraline, or Venlafaxine extended-release (1:1:1 randomization)
Number of subjects: 1008
Study 37318808 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive biotype positive subgroup
Number of subjects: 1008
Study 37318865 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation Facebook Intervention (Chat)
Number of subjects: 22
Study 37318875 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit, feedback, and education intervention (web-based surgical performance feedback dashboard)
Number of subjects: 15000
Study 37318875 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 15000
Study 37318875 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit, feedback, and education intervention
Number of subjects: 15000
Study 37318885 — intervention group
Group type: EXPERIMENTAL
Intervention: Prematurely achieved cardiovascular risk (CVR)
Number of subjects: 218
Study 37318885 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 218
Study 37318885 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum lipid ratios
Number of subjects: 218
Study 37319109 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 0
Study 37319109 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Number of subjects: 0
Study 37319109 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline DLQI mean scores
Number of subjects: 0
Study 37319109 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline POEM mean scores
Number of subjects: 0
Study 37319244 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg modified-release prednisone
Number of subjects: 100
Study 37319244 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 100
Study 37319250 — intervention group
Group type: EXPERIMENTAL
Intervention: Yima Nkqo peer support intervention
Number of subjects: 9
Study 37319354 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised hypertonic saline (3% to 7%)
Number of subjects: 1318
Study 37319354 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised hypertonic saline
Number of subjects: 1318
Study 37319354 — intervention group
Group type: COMPARATOR
Intervention: rhDNase
Number of subjects: 1318
Study 37319432 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg IV every 3 weeks for up to 8 cycles after ASCT.
Number of subjects: 21
Study 37319435 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy
Number of subjects: 20
Study 37319435 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-course pembrolizumab
Number of subjects: 20
Study 37319438 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Octreotide Capsules (OOC)
Number of subjects: 58
Study 37319438 — intervention group
Group type: COMPARATOR
Intervention: Transitioning from injectable somatostatin receptor ligands (iSRLs) to Oral Octreotide Capsules (OOC)
Number of subjects: 58
Study 37319437 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (IV) with a target trough of 10 μg/mL and higher Ctrough_1 (≥39 μg/mL)
Number of subjects: 0
Study 37319437 — intervention group
Group type: COMPARATOR
Intervention: Abatacept (IV) with Ctrough_1 <39 μg/mL
Number of subjects: 0
Study 37319437 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (IV)
Number of subjects: 0
Study 37320999 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP level in patients without heart failure
Number of subjects: 409
Study 37320999 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP level in patients with heart failure
Number of subjects: 409
Study 37320999 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP cut-off value for ruling out heart failure
Number of subjects: 409
Study 37320999 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the receiver operating characteristic curve for diagnosing heart failure
Number of subjects: 409
Study 37321235 — intervention group
Group type: EXPERIMENTAL
Intervention: VLA1553
Number of subjects: 4128
Study 37321235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4128
Study 37321244 — intervention group
Group type: EXPERIMENTAL
Intervention: Reagents containing dextran sulfate (DS)
Number of subjects: 165
Study 37321244 — intervention group
Group type: COMPARATOR
Intervention: Reagents not containing dextran sulfate (DS)
Number of subjects: 165
Study 37321280 — intervention group
Group type: EXPERIMENTAL
Intervention: High maternal EPDS and PSS scores
Number of subjects: 536
Study 37321280 — intervention group
Group type: EXPERIMENTAL
Intervention: One-unit increment in maternal EPDS score
Number of subjects: 536
Study 37321280 — intervention group
Group type: EXPERIMENTAL
Intervention: One-unit increment in maternal PSS score
Number of subjects: 536
Study 37321280 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined high EPDS and PSS scores
Number of subjects: 536
Study 37321280 — intervention group
Group type: COMPARATOR
Intervention: Adjustment for CHAOS score
Number of subjects: 536
Study 37321368 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher functional connectivity (FC) between dorsolateral prefrontal cortex and left frontoparietal and hippocampal areas
Number of subjects: 48
Study 37321368 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased functional connectivity (FC) between basal ganglia and right angular gyrus
Number of subjects: 48
Study 37321368 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fractional anisotropy (FA) in the cingulum bundle and superior longitudinal fasciculus
Number of subjects: 48
Study 37321368 — intervention group
Group type: EXPERIMENTAL
Intervention: Cingulum bundle FA
Number of subjects: 48
Study 37321625 — intervention group
Group type: EXPERIMENTAL
Intervention: Crovalimab
Number of subjects: 44
Study 37321663 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral T4 immunotherapy (CAR-T cells)
Number of subjects: 40
Study 37321665 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT (LDCT) screening
Number of subjects: 11115
Study 37321811 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical correction of pectus excavatum (PE)
Number of subjects: 44
Study 37321955 — intervention group
Group type: EXPERIMENTAL
Intervention: MVC-COV1901
Number of subjects: 144
Study 37321955 — intervention group
Group type: COMPARATOR
Intervention: mRNA-1273
Number of subjects: 144
Study 37322010 — intervention group
Group type: EXPERIMENTAL
Intervention: MAOA variants (rs1137070, rs2064070, rs6323) and TPH2 variants (rs1386494, rs4570625)
Number of subjects: 0
Study 37322121 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapies matched to genomic alterations in 27 substudies
Number of subjects: 1593
Study 37322274 — intervention group
Group type: EXPERIMENTAL
Intervention: IV-golimumab 2 mg/kg at week 0, week 4, then every 8 weeks
Number of subjects: 208
Study 37322274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 37322274 — intervention group
Group type: COMPARATOR
Intervention: Placebo (crossover to IV-golimumab at week 16)
Number of subjects: 208
Study 37322367 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugemalimab plus chemotherapy (1,200 mg every 3 weeks)
Number of subjects: 479
Study 37322367 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 479
Study 37322425 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacoinvasive strategy
Number of subjects: 2710
Study 37322482 — intervention group
Group type: EXPERIMENTAL
Intervention: Latozinemab (single infusion)
Number of subjects: 0
Study 37322482 — intervention group
Group type: COMPARATOR
Intervention: S15JG (anti-sortilin antibody)
Number of subjects: 0
Study 37322482 — intervention group
Group type: EXPERIMENTAL
Intervention: Latozinemab (in cynomolgus monkeys)
Number of subjects: 0
Study 37322506 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus virtual assistant (chatbot)
Number of subjects: 70
Study 37322506 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 70
Study 37322511 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar haemostatic forceps (HemoStat/Pentax®) as experimental therapy (ET)
Number of subjects: 90
Study 37322511 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (ST) using haemoclip + / - epinephrine injection
Number of subjects: 90
Study 37322521 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 890
Study 37322521 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 890
Study 37322537 — intervention group
Group type: EXPERIMENTAL
Intervention: Collastat® (collagen hemostatic matrix, CHM)
Number of subjects: 160
Study 37322537 — intervention group
Group type: COMPARATOR
Intervention: Floseal® (gelatin hemostatic matrix, GHM)
Number of subjects: 160
Study 37322538 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (3 g of probiotic preparation including eight bacterial strains)
Number of subjects: 14
Study 37322538 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic supplementation (5 g of oat bran)
Number of subjects: 14
Study 37322538 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study participation
Number of subjects: 14
Study 37322538 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to participate in a similar study
Number of subjects: 14
Study 37322538 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 14
Study 37322538 — intervention group
Group type: EXPERIMENTAL
Intervention: Feasibility criteria
Number of subjects: 14
Study 37322595 — intervention group
Group type: EXPERIMENTAL
Intervention: Early AMR treatment (more aggressive treatment with plasma exchange and monoclonal/polyclonal antibodies)
Number of subjects: 0
Study 37322595 — intervention group
Group type: COMPARATOR
Intervention: Late AMR treatment (less aggressive treatment)
Number of subjects: 0
Study 37322595 — intervention group
Group type: COMPARATOR
Intervention: Comparison of early vs late AMR
Number of subjects: 0
Study 37322836 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I&N delivered before CPT
Number of subjects: 93
Study 37322836 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I&N delivered after CPT
Number of subjects: 93
Study 37322836 — intervention group
Group type: COMPARATOR
Intervention: CPT alone
Number of subjects: 93
Study 37322842 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 447
Study 37322842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 447
Study 37322892 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive Cardiac Output Monitoring (NICOM)
Number of subjects: 0
Study 37323036 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring follow-up
Number of subjects: 217
Study 37323036 — intervention group
Group type: COMPARATOR
Intervention: Standard-care follow-up
Number of subjects: 217
Study 37323051 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV-targeted T cells
Number of subjects: 0
Study 37323051 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37323059 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2831781 450 mg intravenously (IV)
Number of subjects: 104
Study 37323059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 37323059 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2831781 450 mg IV
Number of subjects: 104
Study 37323099 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg subcutaneously every 6 months)
Number of subjects: 90
Study 37323099 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (70 mg orally once a week)
Number of subjects: 90
Study 37323099 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 90
Study 37323099 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab and Alendronate
Number of subjects: 90
Study 37323125 — intervention group
Group type: EXPERIMENTAL
Intervention: Spark (CBT-based mobile application)
Number of subjects: 60
Study 37323125 — intervention group
Group type: COMPARATOR
Intervention: Active Control (psychoeducational mobile application)
Number of subjects: 60
Study 37323509 — intervention group
Group type: EXPERIMENTAL
Intervention: Messaging on smoking-related COVID-19 risk and cessation support via instant messaging for three months (16 messages in total).
Number of subjects: 1166
Study 37323509 — intervention group
Group type: COMPARATOR
Intervention: Generic text messaging support for three months (16 messages).
Number of subjects: 1166
Study 37323862 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 800
Study 37323862 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 800